Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: